Evolva to Buy U.S. Sweeteners Developer Abunda

Evolva (Reinach, Switzerland), a synthetic biology company, says it has agreed to acquire its R&D partner Abunda Nutrition (San Francisco), a biotech firm involved in developing sweeteners and pharmaceuticals. Under the terms of the proposed merger, Evolva will acquire 100% of the share capital of Abunda in return for 25 million Evolva shares, equivalent to 12.9% of Evolva’s share capital post transaction, fully diluted. If certain value-creating milestones are achieved in the 19 months after closing, Abunda shareholders are entitled to receive up to an...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers